BOEHRINGER-INGELHEIM
3.8.2022 12:07:11 CEST | Business Wire | Press release
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continued to increase its supply of medicine to patients in the first half of 2022, as it expanded its research pipeline in an increasingly challenging economic, political and regulatory environment.
Boehringer Ingelheim has experienced strong momentum through greater investment in Research & Development (R&D), accelerated development of its pipeline and business development opportunities. The company also closed 11 R&D partnership and license deals so far this year, with a focus on new modalities such as protein degraders, antimicrobial resistance, regenerative medicine, oncology and data science.
Fueled by ongoing strong demand for the company’s human heart failure, diabetes and respiratory treatments, and its products for pets, currency-adjusted net sales rose by 9.5 percent to 11.2 billion EUR.
“Despite a volatile economic environment, we were able to supply more patients with the treatments that make a difference to them, while advancing our pipeline in Human Pharma as well as in Animal Health striving to transform lives where medical need is high,” said Hubertus von Baumbach, Chairman of the Board of Managing Directors.
Boehringer Ingelheim has earmarked 25 billion EUR for investments in R&D and an additional 7 billion EUR for new production technologies over the next five years. The company anticipates running eight active human medicines registrational trials by the end of the year, with the potential of bringing 15 new products to patients by 2027.
“Although we expect economic uncertainties to persist in the second half of the year, we remain confident that we can achieve our goals for 2022 and proceed on our innovation-driven path,” said Michael Schmelmer, Member of the Board of Managing Directors, responsible for Finance & Group Functions. “We will continue to focus on and invest in our most promising assets to bring the best value to patients.”
Net sales in Human Pharma were up 11.8 percent (currency-adjusted) during the first six months of 2022 at 8.4 billion EUR, mainly driven by diabetes treatment of the JARDIANCE® family at 2.5 billion EUR and the respiratory medicine OFEV® at 1.5 billion EUR.
Growth in the Animal Health business amounted to 1.2 percent (currency-adjusted) to 2.4 billion EUR. The business was impacted by challenging market conditions including inflation, COVID-19 lockdowns, outbreaks of African Swine Fever and supply chain constraints. Net sales of NEXGARD® , a parasiticide for dogs, increased 13.7 percent (currency-adjusted) to 593 million EUR, while HEARTGARD® , which prevents heartworm disease in dogs, rose 4.4 percent to 197 million EUR.
For the remainder of the year Boehringer Ingelheim is anticipating regulatory updates for Spesolimab, a potential treatment for flares in generalized pustular psoriasis (GPP), a rare, life-threatening neutrophilic skin disease. The company will also present promising data on JARDIANCE® for the treatment of patients with chronic kidney disease. In addition, major product launches are expected for Animal Health in 2022 and 2023.
Click here for the full release: https://www.boehringer-ingelheim.com/about-us/corporate-profile/boehringer-ingelheim-2022-half-year-results
View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005402/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aarhus Vand Selects Netmore for Smart Meter Network25.8.2026 08:00:00 CEST | Press release
Partnership between Netmore, Aarhus Vand, and Kamstrup supports digitalization of metering network and water conservation across Aarhus Municipality, Denmark Netmore Group, the leading network operator and platform provider for Massive IoT, today announced a collaboration with Aarhus Vand and Kamstrup to support the deployment of approximately 69,000 digitally connected water meters across Aarhus Municipality, Denmark. Powered by Netmore's carrier-grade LoRaWAN® network and Kamstrup's digital water metering technology, the project will provide Aarhus Vand with real-time visibility into water consumption while helping residents better understand and reduce their water usage. Rollout begins in Tranbjerg following a successful pilot involving approximately 1,000 households, where the communication between Kamstrup's digital meters and Aarhus Vand was validated. The full deployment will continue through 2030, covering communities across Aarhus Municipality. The new water meters will elimin
Motorola Solutions fuldfører opkøbet af D-Fend Solutions25.8.2026 08:00:00 CEST | Pressemeddelelse
Beskyttelse af luftrummet for beredskabsmyndigheder og kritisk infrastruktur med differentieret, ikke-kinetisk RF-teknologi til cyberovertagelse Motorola Solutions (NYSE: MSI) har gennemført opkøbet af D-Fend Solutions (D-Fend), der er en førende virksomhed inden for anti-drone-teknologi, for en købspris på 1,5 mia. USD. Handlen giver beredskaber og erhvervsliv adgang til avancerede systemer til bekæmpelse af ubemandede luftfartøjer (C-UAS), der er udviklet til sikkert at neutralisere trusler fra uautoriserede droner. "Sikkerhed på jorden kræver sikkerhed i luften," siger Greg Brown, der er bestyrelsesformand og CEO i Motorola Solutions. "D-Fends gennemprøvede anti-drone-teknologi er et stærkt supplement til vores beredskabsløsninger og giver vores kunder verden over en differentieret beskyttelse af luftrummet." Præcis trusselsbegrænsning I modsætning til traditionelle anti-drone-metoder, der baserer sig på simpel detektion efterfulgt af jamming eller nedskydning, identificerer D-Fends
IFF Report Finds GLP-1 Is Reshaping Food Choices and Eating Behaviors Among Indian Consumers25.8.2026 07:30:00 CEST | Press release
Research highlights emerging opportunities for food and beverage innovation IFF (NYSE: IFF) — a global leader in flavors, fragrances and health and biosciences — released new research examining how GLP-1 use is influencing food behaviors among Indian consumers and what those shifts may mean for the future of food and beverage innovation. The study is the latest in IFF’s GLP-1 global consumer insights following the company’s 2025 GLP-1 Consumer Opportunity Outlook. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824816059/en/ “We are seeing that a change in appetite can lead to a broader change in the relationship people have with food, from how much consumers eat to how they choose, experience and participate in eating occasions,” said Harsch Koshti, regional marketing director, IFF Taste for Greater Asia. “For the food industry, this is a critical opportunity to listen closely to these emerging behaviors and think about h
Tigo Energy and Ingeteam Sign Certificate of Compatibility25.8.2026 06:00:00 CEST | Press release
Successful testing between Tigo MLPE and Ingeteam inverters validates an open ecosystem with proven compatibility for European solar installers. Tigo Energy, Inc. (NASDAQ: TYGO), a leading provider of intelligent solar and energy solutions, today announced a Certificate of Compatibility with European energy technology leader, Ingeteam S.A., documenting which Ingeteam inverters and Tigo Flex MLPE products have passed compatibility testing. The certificate covers certain single-phase and three-phase INGECON® SUN products and members of the Tigo TS4 MLPE product family, when properly designed and installed. Together, these products are designed to deliver high-quality, enhanced value with a system that can generate and manage solar energy more efficiently and provide the features that solar energy customers in the residential, Commercial and Industrial (C&I) and Utility segments demand. Ingeteam, a leading decarbonization and energy transformation company building a sustainable future thr
Celltrion Expands Omlyclo® Portfolio in Europe with Launch of 300 mg Strength25.8.2026 00:40:00 CEST | Press release
Omlyclo® (omalizumab) 300 mg launched in key European markets including Germany, the UK and France, with rollout to expand across Europe by year-endOmlyclo® 300 mg strength available in both pre-filled syringe (PFS) and autoinjector (AI) presentationsMultiple dose strengths and device options broaden treatment flexibility for healthcare professionals Celltrion (KRX: 068270) today announced the launch of the 300 mg strength of Omlyclo® (omalizumab), a treatment for chronic spontaneous urticaria and allergic asthma, in Europe.1 With the addition of the 300 mg strength, Celltrion has expanded its Omlyclo® portfolio to include multiple dose strengths and device presentations for patients, healthcare professionals and healthcare institutions. Following the European launch of Omlyclo® 75 mg and 150 mg late last year, Celltrion began rolling out the 300 mg strength in key markets including Germany, the UK and France in the middle of this year. Celltrion is gradually expanding supply to other
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom